
Lundbeck Targets Movement Disorder Breakthroughs at MDS 2026
Lundbeck is set to unveil a broad clinical data set at the International Congress of Parkinson's Disease and Movement Disorders in Seoul, centering on a late-breaking Phase III analysis of amlenetug for multiple system atrophy and new exploratory results for advanced Parkinson's treatment.

















.jpg)









